# Alkermes, Inc. clinical trials: 83 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 83 trials with Alkermes, Inc. as lead sponsor, 7 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Alkermes, Inc.: 83 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/alkermes-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 83
- Recruiting or not yet: 7
- Read on: November 19, 2026

## Trials

The 25 newest of 83, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 28, 2026 | NCT07901179 | A Study to Evaluate the Safety and Efficacy of ALKS 7290 as an Adjunctive Therapy to Antidepressants in Adult Participants With Major... | Alkermes, Inc. | Phase 2 | Recruiting | Major Depressive Disorder (MDD) | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901179) |
| August 10, 2026 | NCT07755410 | A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity... | Alkermes, Inc. | Phase 2 | Recruiting | Attention Deficit Disorder With Hyperactivity (ADHD) | 312 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07755410) |
| August 4, 2026 | NCT07744113 | An Expanded Access Program (EAP) for OLZ/SAM in Pediatric Participants With Schizophrenia or Bipolar I Disorder (ALKS 3831-315) | Alkermes, Inc. | Not applicable | Available | Bipolar 1 Disorder, Schizophrenia Disorder | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07744113) |
| April 21, 2026 | NCT07540897 | A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) | Alkermes, Inc. | Phase 3 | Recruiting | Narcolepsy Type 1 | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07540897) |
| March 31, 2026 | NCT07502443 | A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 | Alkermes, Inc. | Phase 3 | Recruiting | Narcolepsy Type 2 | 176 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502443) |
| March 6, 2026 | NCT07455383 | A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | Alkermes, Inc. | Phase 3 | Recruiting | Narcolepsy Type 1 | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07455383) |
| February 25, 2025 | NCT06843590 | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | Alkermes, Inc. | Phase 2 | Active not recruiting | Idiopathic Hypersomnia | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06843590) |
| January 10, 2025 | NCT06767683 | A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia | Alkermes, Inc. | Phase 2/3 | Recruiting | Narcolepsy Type 1, Narcolepsy Type 2, Idiopathic Hypersomnia | 786 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06767683) |
| August 15, 2024 | NCT06555783 | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 | Alkermes, Inc. | Phase 2 | Completed | Narcolepsy Type 2 | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06555783) |
| April 11, 2024 | NCT06358950 | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201) | Alkermes, Inc. | Phase 2 | Completed | Narcolepsy Type 1 | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06358950) |
| September 21, 2022 | NCT05547100 | Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan | Alkermes, Inc. | Phase 1 | Completed | Focus of Study is on Healthy Lactating Women | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05547100) |
| March 31, 2022 | NCT05303064 | Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder | Alkermes, Inc. | Phase 3 | Recruiting | Schizophrenia, Bipolar I Disorder | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05303064) |
| August 24, 2021 | NCT05019105 | Phase 1 ALKS 1140 in Healthy Adults | Alkermes, Inc. | Phase 1 | Terminated | Central Nervous System Diseases | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05019105) |
| August 3, 2021 | NCT04987658 | Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder | Alkermes, Inc. | Phase 1 | Completed | Bipolar I Disorder | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04987658) |
| August 3, 2021 | NCT04987229 | Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects | Alkermes, Inc. | Phase 3 | Enrolling by invitation | Bipolar I Disorder, Schizophrenia | 236 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04987229) |
| May 28, 2019 | NCT03963973 | A 28 Day Parallel Group Study to Assess the Effects of RDN-929 | Alkermes, Inc. | Phase 1 | Terminated | Healthy | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03963973) |
| April 18, 2019 | NCT03919994 | Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS) | Alkermes, Inc. | Observational | Completed | Schizophrenia | 338 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03919994) |
| September 12, 2018 | NCT03668314 | Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly Subjects | Alkermes, Inc. | Phase 1 | Completed | Healthy | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03668314) |
| August 1, 2018 | NCT03610048 | A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD) | Alkermes, Inc. | Phase 3 | Terminated | Refractory Major Depressive Disorder | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03610048) |
| July 5, 2018 | NCT03577262 | A Non-therapeutic Feasibility Study of the Radioligand \[11C\]-UCB-J for Imaging Synaptic Density | Alkermes, Inc. | Early phase 1 | Completed | Healthy, Alzheimer Disease | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03577262) |
| November 17, 2017 | NCT03345979 | A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia | Alkermes, Inc. | Phase 3 | Completed | Schizophrenia | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03345979) |
| June 28, 2017 | NCT03201757 | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | Alkermes, Inc. | Phase 3 | Completed | Schizophrenia, Schizophreniform Disorder, Bipolar I Disorder | 523 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03201757) |
| June 15, 2017 | NCT03188185 | A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD) | Alkermes, Inc. | Phase 3 | Completed | Major Depressive Disorder | 278 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03188185) |
| June 15, 2017 | NCT03187769 | Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia... | Alkermes, Inc. | Phase 3 | Completed | Schizophrenia, Schizophreniform Disorders, Bipolar I Disorder | 426 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03187769) |
| October 4, 2016 | NCT02922426 | An Insulin Sensitivity Study in Healthy Subjects | Alkermes, Inc. | Phase 1 | Completed | Healthy Volunteers | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02922426) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 24 |
| Phase 1/2 | 1 |
| Phase 2 | 17 |
| Phase 2/3 | 1 |
| Phase 3 | 33 |
| Phase 4 | 3 |
| Not applicable | 1 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 68 |
| Recruiting | 7 |
| Terminated | 5 |
| Enrolling by invitation | 1 |
| Active not recruiting | 1 |
| Available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Schizophrenia | 21 |
| Alcoholism | 11 |
| Depressive Disorder, Major | 10 |
| Opioid-Related Disorders | 8 |
| Disorders of Excessive Somnolence | 7 |
| Sleep Wake Disorders | 6 |
| Depression | 5 |
| Narcolepsy | 4 |
| Behavior, Addictive | 4 |
| Psychotic Disorders | 3 |
| Idiopathic Hypersomnia | 2 |
| Cataplexy | 2 |
| Opioid-Induced Constipation | 2 |
| Body Weight | 1 |
| Pulmonary Disease, Chronic Obstructive | 1 |
| Respiratory Aspiration | 1 |
| Binge-Eating Disorder | 1 |
| Heroin Dependence | 1 |
| Meningitis, Cryptococcal | 1 |
| HIV Infections | 1 |
| AIDS-Related Opportunistic Infections | 1 |
| Meningitis | 1 |
| Acquired Immunodeficiency Syndrome | 1 |
| Sleepiness | 1 |
| Central Nervous System Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pediatric nephrology practices in the United States](https://specstream.ai/data/businesses/pediatric-nephrology-practices/united-states)
- [Medical sciences schools in the United States](https://specstream.ai/data/businesses/medical-sciences-schools/united-states)
- [Insulation contractors in the United States](https://specstream.ai/data/businesses/insulation-contractors/united-states)
- [Gastroenterology practices in the United States](https://specstream.ai/data/businesses/gastroenterology-practices/united-states)
- [Electricians in the United States](https://specstream.ai/data/businesses/electricians/united-states)
- [Colombian restaurants in the United States](https://specstream.ai/data/businesses/colombian-restaurants/united-states)
